3 Rapaport Street
CathWorks develops medical devices for the interventional cardiology market.
Please click here for CathWorks job opportunities.
14 articles with Cathworks
The CathWorks FFRangio System transforms routine angiogram images into objective and comprehensive physiology information, including a color-coded 3D renderings of blood flow in the heart's arteries to help physicians optimize coronary artery disease decision making, including whether a stent is needed.
Mr. Feher will initially focus on the development of financial and operational capabilities, as well as creating value for the organization through the execution of company’s strategy.
Deerfield Management Leads Series C Financing
Provides Experienced Commercial Leadership For CathWorks FFRangio™ U.S. Launch
Enables non-invasive, objective functional evaluation of multi-vessel coronary artery disease
Trial Results Published in Circulation
he CathWorks FFRangio™ System will be featured in a TCT Lunch Presentation Theater Program held during the 2018 TCT (Transcatheter Cardiovascular Therapeutics) annual meeting in San Diego.
CathWorks announced that the FAST-FFR pivotal trial has been added to the late-breaking clinical science program during the 2018 TCT (Transcatheter Cardiovascular Therapeutics) annual meeting in San Diego. FAST-FFR trial data will be presented in the Main Arena during the late-breaking science session that begins at 12 noon on Monday, September 24.
CathWorks announced that it has submitted its CathWorks FFRangio™ System to the United States Food & Drug Administration (FDA) for review and 510(k) market clearance.
CathWorks announced that its FAST-FFR trial is fully enrolled ahead of schedule.
CathWorks Receives CPT Code for New Wire-Free, Intraprocedural FFR Measurements to Optimize PCI Therapy Decisions
CathWorks announced the approval of a new CPT code 0523T for non-invasive, 3D FFRangio™ enabled interpretation of possible atherosclerotic stenosis during coronary angiography interventions.
CathWorks announced today the appointment of James M. Corbett as its CEO.
Cathworks announced today that the first patient has been enrolled in the FAST-FFR clinical trial.